Role of stem-cell transplantation in leukemia treatment

G Dessie, M Derbew Molla, T Shibabaw… - Stem cells and cloning …, 2020 - Taylor & Francis
Stem cells (SCs) play a major role in advanced fields of regenerative medicine and other
research areas. They are involved in the regeneration of damaged tissue or cells, due to …

Nilotinib vs. imatinib in Japanese patients with newly diagnosed chronic myeloid leukemia in chronic phase: 10-year follow‑up of the Japanese subgroup of the …

H Nakamae, M Yamamoto, E Sakaida, Y Kanda… - International Journal of …, 2022 - Springer
In the 10-year analysis of Japanese patients with newly diagnosed CML-CP in the ENESTnd
trial, nilotinib yielded higher cumulative response rates. There were no new occurrences of …

[HTML][HTML] Potential to improve therapy of chronic myeloid leukemia (CML), especially for patients with older age: incidence, mortality, and survival rates of patients with …

M Daskalakis, A Feller, J Noetzli, N Bonadies, V Arndt… - Cancers, 2021 - mdpi.com
Simple Summary In a population-based study of chronic myeloid leukemia (CML) patients in
Switzerland, we confirmed an increase in relative survival for all age groups over the last …

[HTML][HTML] Targeting abnormal hematopoietic stem cells in chronic myeloid leukemia and philadelphia chromosome-negative classical myeloproliferative neoplasms

Y Yung, E Lee, HT Chu, PK Yip, H Gill - International journal of molecular …, 2021 - mdpi.com
Myeloproliferative neoplasms (MPNs) are unique hematopoietic stem cell disorders sharing
mutations that constitutively activate the signal-transduction pathways involved in …

[HTML][HTML] A customized mass array panel for BCR:: ABL1 tyrosine kinase domain mutation screening in chronic myeloid leukemia

N Limsuwanachot, B Rerkamnuaychoke… - Journal of Mass …, 2023 - Elsevier
Introduction The therapeutic strategy and management of chronic myeloid leukemia (CML)
have rapidly improved with the discovery of effective tyrosine kinase inhibitors (TKIs) to …

Real-world therapeutic response and tyrosine kinase inhibitor discontinuation in chronic phase-chronic myeloid leukemia: data from the French observatory

S Saugues, C Lambert, E Daguenet, HJ Ansah… - Annals of …, 2022 - Springer
Guidelines for tyrosine kinase inhibitor (TKI)-treated chronic phase-chronic myeloid
leukemia (CML) management are essentially based on data from clinical research trials; …

[HTML][HTML] Proteomic Analysis Reveals Trilaciclib-Induced Senescence

M Hermosilla-Trespaderne, MX Hu-Yang… - Molecular & Cellular …, 2024 - ASBMB
Trilaciclib, a cyclin-dependent kinase 4/6 inhibitor, was approved as a myeloprotective agent
for protecting bone marrow from chemotherapy-induced damage in extensive-stage small …

Chronic myeloid leukemia (CML) evolves from Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) with unexpected frequency

MJ Hochman, BD Smith, T Karantanos… - International journal of …, 2023 - Springer
Myeloproliferative neoplasms (MPN) are chronic clonal disorders characterized by
overproduction of myeloid-lineage blood cells and potential risk of evolution to acute …

Oncogenic fusions in gliomas: An institutional experience

J Polivka, M Svajdler, V Priban, J Mracek… - Anticancer …, 2022 - ar.iiarjournals.org
Background/Aim: Gliomas are primary malignancies of the central nervous system (CNS).
High-grade gliomas are associated with poor prognosis and modest survival rates despite …

[HTML][HTML] Repurposing pexmetinib as an inhibitor of TKI-resistant BCR:: ABL1

D Fontana, F Malighetti, M Villa, A Zambon… - Leukemia, 2024 - nature.com
Chronic myeloid leukemia (CML) is a clonal disorder caused by the Philadelphia (Ph)
chromosome encoding for the BCR:: ABL1 fusion gene [1]. The development of imatinib and …